Stockscreener 앱 받기
1.00
0.00%
0.00
Inflarx N V 주식(IFRX)의 최신 뉴스
Bank Watch: Is Montauk Renewables Inc a potential multi baggerWatch List & Low Drawdown Momentum Ideas - baoquankhu1.vn
Bull Run: Why InflaRx N.V. (IF0) stock could rally stronglyJuly 2025 Levels & Weekly High Potential Stock Alerts - Bộ Nội Vụ
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Pullback Watch: Will InflaRx NV stock recover faster than market2025 Key Highlights & Daily Profit Maximizing Tips - Bộ Nội Vụ
Is InflaRx N.V. stock a top pick in earnings season2025 Fundamental Recap & Intraday High Probability Setup Alerts - Улправда
Why InflaRx N.V. stock remains on buy listsWeekly Investment Recap & Reliable Breakout Stock Forecasts - Улправда
How InflaRx N.V. stock valuations compare to rivalsInflation Watch & Technical Pattern Recognition Alerts - Улправда
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027 - TipRanks
Will InflaRx N.V. stock recover faster than market2025 Top Gainers & Advanced Swing Trade Entry Alerts - Улправда
Why is InflaRx Stock Falling Today?InflaRx (NASDAQ:IFRX) - Benzinga
InflaRx stock falls after announcing restructuring and pipeline prioritization By Investing.com - Investing.com India
InflaRx stock falls after announcing restructuring and pipeline prioritization - Investing.com
InflaRx to prioritize izicopan development, cuts workforce by 30% - Investing.com South Africa
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation - GlobeNewswire
What analysts say about InflaRx NV IF0 stockPrice Support Zones & Follow Top Performers in the Community - earlytimes.in
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
InflaRx (IFRX) stock: biotech battleground after a volatile quarter and shifting expectations - AD HOC NEWS
InflaRx NV Is Exploding: Hidden Biotech Underdog or Just Another Hype Trap? - AD HOC NEWS
Raymond James reiterates Outperform rating on Inflarx stock at $9 target - Investing.com
Short Interest in InflaRx N.V. (NASDAQ:IFRX) Increases By 26.7% - MarketBeat
InflaRx reports potential efficacy signals in failed PG drug trial By Investing.com - Investing.com Nigeria
InflaRx (IFRX) Shares Mixed Results from Vilobelimab Phase 3 Trial in Ulcerative PG - parameter.io
InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt - MSN
Momentum Shift: Is InflaRx NV stock a top pick in earnings seasonLong Setup & Growth-Oriented Investment Plans - Bộ Nội Vụ
InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright - MarketBeat
InflaRx Reports Efficacy Signals In Terminated Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum - Nasdaq
InflaRx Shares In-Dept Analysis About Vilobelimab, Stock Down In Pre-Market - Nasdaq
InflaRx reports potential efficacy signals in failed PG drug trial - Investing.com
InflaRx N.V. Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum - marketscreener.com
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum - Sahm
Published on: 2025-12-24 04:49:46 - moha.gov.vn
Analysts Set InflaRx N.V. (NASDAQ:IFRX) Price Target at $7.50 - Defense World
Why InflaRx N.V. (IF0) stock trades below fair valuePortfolio Return Summary & Expert Verified Movement Alerts - Улправда
Is InflaRx N.V. stock a buy in volatile marketsTrade Exit Summary & Weekly High Return Stock Forecasts - DonanımHaber
Why InflaRx N.V. stock is a value investor pick2025 Earnings Surprises & AI Powered Trade Plan Recommendations - DonanımHaber
Is InflaRx N.V. stock positioned for digital transformationJuly 2025 Patterns & Low Drawdown Trading Techniques - DonanımHaber
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Understanding IFRX’s book value per share for better investment insights - uspostnews.com
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug - MSN
InflaRx NV Stock Analysis and ForecastStock Split Announcements & Big Gains Low Investment - earlytimes.in
Can Northern Spirits Limited Outperform Index Funds Over the Next 5 YearsAnalyst Downgrades & Small Investment Big Gains - earlytimes.in
InflaRx’s oral C5aR inhibitor receives WHO generic name izicopan By Investing.com - Investing.com South Africa
InflaRx’s oral C5aR inhibitor receives WHO generic name izicopan - Investing.com India
InflaRx Announces International Nonproprietary Name of 'Izicopan” for INF904 - The Manila Times
InflaRx N.V. Announces WHO Grant of International Nonproprietary Name “izicopan” for C5aR Inhibitor INF904 - Quiver Quantitative
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904 - Yahoo Finance
Gap Down: Why InflaRx NV stock is a value investor pickMarket Trend Review & Safe Entry Zone Tips - moha.gov.vn
4.73%
0.92%
자본화:
|
볼륨(24시간):